Following adjustment for age, sex, SBP, baseline eGFR, PVD, diabetes, primary renal disease classification, and baseline usage of aspirin or ACEi/ARB medications, high sCD40L was independently predictive of a decline in eGFR percent change at 1-year follow-up (−7.57%, p = 0.014). This evidence concerns the gene CD40LG and diabetes mellitus.